###### Strengths and limitations of this study

-   This is the first large-scale population-based cohort study to evaluate the relationship between the use of proton pump inhibitors (PPIs) and the risk of pneumonia in patients with non-traumatic intracranial haemorrhage. Moreover, the strong evidence base can be used to investigate the causal relationship.

-   The study from the National Health Insurance database is representative of the study sample, and the study population is large enough for stratified analysis of the different disease-severity groups.

-   Since our study comes from National Health Insurance claims data, its major limitation is lack of clinical information. There are no laboratory data and no disease severity measures such as Glasgow Coma Scale, Modified Rankin Scale or National Institutes of Health Stroke Scale scores for the studied patients.

-   Other study limitations include the unavailability of potential lifestyle factors and patients' medication compliance, which could potentially confound the relationship between the use of PPIs and risk of pneumonia.

Introduction {#s1}
============

Pneumonia is an inflammatory condition of the lung that involves the pulmonary parenchyma and develops through proliferation of microbial pathogens at the alveolar level of the respiratory tract and the response of the host.[@R1] Moreover, it is an infectious disease that is associated with considerable morbidity and mortality, and is the most common fatal infection acquired in hospitals, causing the deaths of 3.2 million people worldwide in 2011. In Taiwan, pneumonia was the fourth leading cause of death in 2012 according to the statistics of the Ministry of Health and Welfare.[@R5] [@R6] Stroke patients commonly experience cardiac complications, pneumonia, thromboembolism, gastrointestinal bleeding and urinary tract infection, which require prompt diagnosis and management. It has been shown that, of these complications, pneumonia plays the most vital role in the inter-relationship.[@R7] [@R8] Therefore preventing pneumonia is vital to reducing morbidity and mortality, especially in stroke patients. Most stroke-related pneumonia is believed to result from aspiration. Gastrointestinal symptoms often occur in patients with non-traumatic intracranial haemorrhage (ICH), and proton pump inhibitors (PPIs) are therapeutically indicated for gastrointestinal disorders involving excessive acid production.[@R9] However, it has been reported that using acid-suppressive medication such as a PPI increases the risk of pneumonia in older people.[@R10] Several studies have confirmed that using prophylactic PPIs during an acute non-traumatic ICH stroke can increase the risk of hospital-acquired pneumonia through acute and irreversible gastric acid suppression.[@R13] However, the relationship between short-term and long-term PPI use and pneumonia in patients with non-traumatic ICH has not been determined. The purpose of this study was to investigate the association between PPI use and pneumonia in patients with non-traumatic ICH using a nationwide-based dataset.

Methods and materials {#s2}
=====================

Data sources {#s2a}
------------

A retrospective cohort population-based study was conducted using registration and claims datasets from 2010 to 2011 obtained from the Longitudinal Health Insurance Database 2010 (LHID2010), a subset of the National Health Insurance Research Database (NHIRD), which is managed by the Taiwanese National Health Research Institutes (NHRI). The LHID2010 contains all ambulatory and inpatient claims data on one million beneficiaries who were randomly sampled from the 2010 registry for beneficiaries of the NHIRD, and we used these data to examine the association between PPI use and pneumonia in patients with non-traumatic ICH with up to 2 years of follow-up ([figure 1](#BMJOPEN2014006710F1){ref-type="fig"}). We used age- and sex-matched control for these two cofounding factors, so that our study could use propensity score matching for rigorous statistical matching, which can effectively identify the characteristics of similar groups. However, some information may be lost if over-matching because, again, the matched factors cannot be used to analyse between the disease and other factors. These databases have previously been used in numerous medical studies and have proven to be of high quality.[@R14] This study was approved by the Institutional Review Board of Chung Shan Medical University Hospital (CSMU No 14056). Because all personal data in the secondary files were deidentified before they were analysed, the review board waived the requirement to obtain written informed consent from the patients.

![Flow chart for selecting patients with non-traumatic intracranial haemorrhage (ICH).](bmjopen2014006710f01){#BMJOPEN2014006710F1}

Study sample and setting {#s2b}
------------------------

Patients aged \>18 years who had non-traumatic ICH were included in the study. We defined non-traumatic ICH according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 430, 431 and 432.xx. Pneumonia was defined according to ICD-9-CM codes 481, 482.xx, 483.xx, 485 and 486 ([table 1](#BMJOPEN2014006710TB1){ref-type="table"}). We analysed data on all patients with non-traumatic ICH from 1 January 2010 to 31 December 2010. The average follow-up was 1.05 years. We first excluded patients aged under 18 years and then those newly diagnosed with non-traumatic ICH complicated with pneumonia during the same admission period, because the primary objective of this study was to observe whether patients with non-traumatic ICH using PPIs developed pneumonia. Patients who had a history of pneumonia in the year before PPI treatment was initiated were also excluded. The study cohort comprised 3982 patients with non-traumatic ICH. These patients were divided into PPI and non-PPI groups. [Figure 1](#BMJOPEN2014006710F1){ref-type="fig"} shows the study framework. Five PPI medications are available in Taiwan, namely omeprazole, pantoprazole, lansoprazole, esomeprazole and rabeprazole. We excluded the intravenous form of PPI because it is usually administered under acute conditions. To measure drug use, we used the defined daily dose (DDD), which was recommended by the WHO.[@R17] Cumulative DDDs were estimated as the sum of the dispensed DDD of any PPI and the final use during the study observation time period.

###### 

ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes used to identify disease categories

  ICD-9-CM code         Diagnosis
  --------------------- -------------------------------------------------
  *Pneumonia*           
  481                   Pneumococcal pneumonia
  482                   Other bacterial pneumonia
  482.0                 Pneumonia due to *Klebsiella pneumoniae*
  482.1                 Pneumonia due to *Pseudomonas*
  482.2                 Pneumonia due to *Haemophilus influenzae*
  482.3                 Pneumonia due to *Streptococcus*
  482.30                Pneumonia due to *Streptococcus*, unspecified
  482.31                Pneumonia due to *Streptococcus*, Group A
  482.32                Pneumonia due to *Streptococcus*, Group B
  482.39                Pneumonia due to other *Streptococcus*
  482.4                 Pneumonia due to *Staphylococcus*
  482.40                Pneumonia due to *Staphylococcus*, unspecified
  482.41                Pneumonia due to *Staphylococcus aureus*
  482.49                Pneumonia due to other *Staphylococcus*
  482.8                 Pneumonia due to other specified bacteria
  482.81                Pneumonia due to *Anaerobes*
  482.82                Pneumonia due to *Escherichia coli*
  482.83                Pneumonia due to other Gram-negative bacteria
  482.84                Legionnaires' disease
  482.89                Other specified bacteria
  482.9                 Bacterial pneumonia, unspecified
  483                   Pneumonia due to other specified organism
  483.0                 Pneumonia due to *Mycoplasma pneumoniae*
  483.1                 Pneumonia due to *Chlamydia*
  483.8                 Pneumonia due to other specified organism
  485                   Bronchopneumonia, organism unspecified
  486                   Pneumonia, organism unspecified
  *Non-traumatic ICH*   
  430                   Subarachnoid haemorrhage
  431                   Intracerebral haemorrhage
  432                   Other and unspecified intracerebral haemorrhage
  432.0                 Non-traumatic extradural haemorrhage
  432.1                 Subdural haemorrhage
  432.9                 Unspecified ICH

ICH, intracranial haemorrhage.

In addition, we collected information on age, sex, monthly income, urbanisation and comorbidities. Comorbidities were represented using the Charlson Comorbidity Index (CCI) as described in previous studies.[@R18] The comorbidities considered in the CCI score were myocardial infarction (ICD-9-CM 410−410.9, 412), congestive heart failure (ICD-9-CM 428−428.9), peripheral vascular disease (ICD-9-CM 443.9, 441, 441.9, 785.4, V43.4), cerebrovascular disease (ICD-9-CM 430−437, 438), dementia (ICD-9-CM 290−290.9), chronic pulmonary disease (ICD-9-CM 490−496, 500−505, 506.4), rheumatologic disease (ICD-9-CM 710, 710.1, 710.4, 714−714.2, 714.81, 725), peptic ulcer disease (ICD-9-CM 531−534.9, 531.4−531.7, 532.4−532.7, 533.4−533.7, 534.4--534.7), mild liver disease (ICD-9-CM 571.2, 571.5, 571.6, 571.4−571.49), diabetes (ICD-9-CM 250−250.3, 250.7), diabetes with chronic complications (ICD-9-CM 250.4−250.6), hemiplegia or paraplegia (ICD-9-CM 344.1, 342−342.9), renal disease (ICD-9-CM 582−582.9, 583−583.7, 585, 586, 588−588.9), malignancies including leukaemia and lymphoma (ICD-9-CM 140−172.9, 174−195.8, 200−208.9), moderate and severe liver disease (ICD-9-CM 572.2−572.8, 456.0−456.21), metastatic solid tumours (ICD-9-CM 196−199.1), and acquired immune deficiency syndrome (ICD-9-CM 042.0−044.9).

Statistical analysis {#s2c}
--------------------

Categorical variables are presented as counts and percentages and were compared using the χ^2^ test where appropriate. Continuous data are presented as mean±SD and were compared using the independent t test. Cox proportional hazard model analysis was performed to estimate the HR of pneumonia in the PPI group and the non-PPI group. In addition, we adjusted for potential confounding factors that may have influenced calculation of the risk of pneumonia development, namely age, sex, CCI, monthly income, and urbanisation. Statistical analysis was performed using SPSS V.18.0. A p value \<0.05 was considered to indicate significance. Development of pneumonia was assessed using Kaplan--Meier analysis, in which significance was based on the log rank test.

Results {#s3}
=======

We identified 4644 patients with non-traumatic ICH over the 1-year study period. After patients diagnosed at \<18 years of age (N=89) and those who had a history of pneumonia within the preceding year (N=573) had been excluded, the sample consisted of 3982 patients (434 in the PPI group and 3548 in the non-PPI group). The patient age ranged from 18 to 100 years, and the mean±SD ages in the PPI group and non-PPI group were 66.43±14.90 years and 65.52±15.51 years, respectively. The patients who were diagnosed with ICH were predominantly male (64.52%). After the patients had been matched, the CCIs of 21.95%, 51.9% and 26.15% of the patients in the PPI group were 0, 1 and ≥2, respectively. [Table 2](#BMJOPEN2014006710TB2){ref-type="table"} shows demographic, comorbidity and clinical data on the patients with non-traumatic ICH who did and did not use PPIs.

###### 

Baseline demographic and clinical data on patients with non-traumatic intracranial haemorrhage who did or did not use proton pump inhibitors (PPIs) in Taiwan in 2010 (N=3982) as well as the matched cohort (N=2170)

                   Unmatching\*                 Matching\*                                                              
  ---------------- -------------- ------------- ------------ ------------- ------------- ------- ------- ------ ------- ---------
  Gender                                                                   0.244                                        1.000
   Female          154            35.48         1361         38.36                       154     35.48   616    35.48   
   Male            280            64.52         2187         61.64                       280     64.52   1120   64.52   
  Age, years                                                               \<0.001                                      1.000
   18--39          26             5.99          402          11.33                       26      5.99    104    5.99    
   40--64          158            36.41         1640         46.22                       158     36.41   632    36.41   
   ≥65             250            57.60         1506         42.45                       250     57.60   1000   57.6    
   Mean±SD         66.43±14.90    60.89±16.58   \<0.001      66.43±14.90   65.52±15.51   0.195                          
  Track duration   1.05±0.68      1.08±0.72     0.463        1.05±0.68     1.05±0.73     0.855                          
  Monthly income                                                           0.864                                        0.776
   ≤NT\$19200      256            58.99         2108         59.41                       256     58.99   1037   59.74   
   \>NT\$19200     178            41.01         1440         40.59                       178     41.01   699    40.26   
  Urbanisation                                                             0.074                                        0.278
   Urban           241            55.53         1937         54.59                       241     55.53   937    53.97   
   Suburban        125            28.80         1169         32.95                       125     28.80   562    32.37   
   Rural           68             15.67         442          12.46                       68      15.67   237    13.65   
  CCI                                                                      \<0.001                                      \<0.001
   0               28             6.45          932          26.27                       28      6.45    381    21.95   
   1               227            52.30         1751         49.35                       227     52.30   901    51.9    
   ≥2              179            41.24         865          24.38                       179     41.24   454    26.15   

\*For gender and age.

CCI, Charlson Comorbidity Index.

The crude HR results indicate that the pneumonia risk of patients who used PPIs was 1.70 times greater than that of the patients in the non-PPI group (95% CI 1.40 to 2.08). Patients aged over 65 years were associated with a higher probability of developing pneumonia than were those aged 18−39 years (adjusted HR=2.62, 95% CI 1.49 to 4.59). Moreover, men exhibited a significantly higher probability of developing pneumonia than women (adjusted HR=1.36, 95% CI 1.12 to 1.66). Furthermore, a CCI≥1 was associated with a significantly higher probability of developing pneumonia (CCI=1, Adjusted HR=1.62, 95% CI 1.15 to 2.27; CCI≥2, Adjusted HR=1.58, 95% CI 1.11 to 2.27), as illustrated in [table 3](#BMJOPEN2014006710TB3){ref-type="table"}. A DDD of PPI \<60 was associated with a significantly increased risk of pneumonia compared with a DDD of 0 (non-PPI group). However, no significant difference in the risk of pneumonia was observed between a DDD of PPI \> 60 and a DDD of 0 (non-PPI group), as illustrated in [table 4](#BMJOPEN2014006710TB4){ref-type="table"}. Thus, the risk of pneumonia varied according to the cumulative dose of PPI.

###### 

Cox proportional HR of pneumonia between patients with non-traumatic intracranial haemorrhage who used proton pump inhibitors (PPIs) (N=434) and those who did not use PPIs (N=1736)

                                           95% CI          95% CI            
  ---------------- ------ ----- ---------- -------- ------ ---------- ------ ------
  PPI                                                                        
   No              1736   326   1                          1                 
   Yes             434    142   1.70\*\*   1.40     2.08   1.61\*\*   1.32   1.97
  Gender                                                                     
   Female          770    151   1                          1                 
   Male            1400   317   1.11       0.92     1.35   1.36\*\*   1.12   1.66
  Age, years                                                                 
   18--39          130    13    1                          1                 
   40--64          790    112   1.24       0.70     2.20   1.22       0.69   2.17
   ≥65             1250   343   2.73\*\*   1.57     4.76   2.62\*\*   1.49   4.59
  Monthly income                                                             
   ≤NT\$19200      1293   309   1                          1                 
   \>NT\$19200     877    159   0.76\*\*   0.63     0.92   0.81\*     0.66   0.99
  Urbanisation                                                               
   Urban           1178   250   1                          1                 
   Suburban        687    141   0.98       0.79     1.20   1.02       0.82   1.25
   Rural           305    77    1.25       0.96     1.61   1.22       0.94   1.59
  CCI                                                                        
   0               409    40    1                          1                 
   1               1128   273   2.23\*\*   1.60     3.11   1.62\*\*   1.15   2.27
   ≥2              633    155   2.30\*\*   1.62     3.25   1.58\*     1.11   2.27

\*p\<0.05, \*\*p\<0.01.

CCI,Charlson Comorbidity Index.

###### 

Dose effect analysis of patients with non-traumatic intracranial haemorrhage who received proton pump inhibitor (PPI) therapy attributable to pneumonia

                                       95% CI          95% CI            
  ------------ ------ ----- ---------- -------- ------ ---------- ------ ------
  None         1736   326   1                          1                 
  \<30 DDD     172    70    2.62\*\*   2.02     3.39   2.60\*\*   2.01   3.38
  30--60 DDD   70     24    2.21\*\*   1.46     3.34   2.04\*\*   1.34   3.10
  61--90 DDD   34     7     0.91       0.43     1.92   0.80       0.38   1.68
  \>90 DDD     158    41    1.08       0.78     1.50   1.00       0.72   1.39

\*\*p\<0.01.

†Adjusted for gender, age, income, urbanisation, Charlson Comorbidity Index.

DDD, defined daily dose.

[Figure 2](#BMJOPEN2014006710F2){ref-type="fig"} shows Kaplan--Meier curves of the occurrence of pneumonia in patients with non-traumatic ICH in the PPI and non-PPI groups with various CCI scores. [Figures 2](#BMJOPEN2014006710F2){ref-type="fig"}A--C show CCI scores of 0, 1 and ≥2, and [figure 2](#BMJOPEN2014006710F2){ref-type="fig"}D shows the overall CCI. The overall CCI was associated with a significant increase in the cumulative incidence of pneumonia in the PPI group compared with the non-PPI group.

![Kaplan--Meier curves of the occurrence of pneumonia in patients with non-traumatic intracranial haemorrhage who used proton pump inhibitors (PPIs) and those who did not use PPIs. (A) Charlson Comorbidity Index (CCI)=0; (B) CCI=1; (C) CCI≥2; (D) overall CCI.](bmjopen2014006710f02){#BMJOPEN2014006710F2}

Discussion {#s4}
==========

According to our thorough review of relevant research, this study is the first to explore the association between PPI and pneumonia in patients with non-traumatic stroke using a nationwide dataset. The strength of this cohort study is the use of the LHID2010 nationwide database. In Taiwan, the National Health Insurance system has covered the medical service use of nearly 98% of the Taiwanese population since 1995; thus, the data accurately represent the medical situation in Taiwan. The incidence of pneumonia in this study group was 11.8%, which is similar to that reported by a previous cohort study conducted in the UK (13.8%).[@R21]

Non-traumatic ICH pneumonia is associated with an adverse outcome, a prolonged hospital stay, and increased health costs. In this large population-based study, we observed that PPI administration was strongly associated with pneumonia. PPI administration is the leading treatment for acid-related gastrointestinal disorders. Gastro-oesophageal reflux and gastric ulcer bleeding are common complications of stroke that can be managed using PPIs.[@R22] However, when gastric acid secretion is suppressed, gastric bacterial overgrowth can contribute to aspiration pneumonia.[@R23] Several previous studies have reported that PPI therapy is associated with an increased risk of community-acquired pneumonia.[@R11] [@R12] [@R24] DDD, the cumulative dose of PPI drug, is divided into five groups. The 'never used PPI' population numbered 1736, and the cumulative dose in this group was none; other groups were formed according to the cumulative dose of PPI drug divided into \<30, 30--60, 61--90 and \>90 DDD. However, our results reveal that an association can be established during short-term PPI therapy (\<30 and 30−60 DDD, HR 2.60 (95% CI 2.01 to 3.38), p\<0.001 and HR 2.04 (95% CI 1.34 to 3.10), p\<0.001, respectively). We observed that long-term PPI use does not increase the risk of community-acquired pneumonia. This result is similar to that reported by Sarkar *et al*,[@R25] who observed that PPI therapy initiated within the preceding 30 days was associated with an increased risk of community-acquired pneumonia, whereas long-term current use was not. Ran *et al*[@R13] observed that using PPI as a prophylactic treatment for stress-related mucosal damage was associated with a higher occurrence of nosocomial pneumonia in the ICH population. In our study, we excluded patients with nosocomial pneumonia during the acute ICH phase to eliminate potential confounding factors such as intubation and mechanical-ventilation-associated pneumonia.

The CCI is a scoring system that is commonly used to measure patients' comorbid conditions. Although CCI was first really get inside comorbidity weighted values from survival analysis, in most healthcare research it is also used as disease severity adjustment. The Index encompasses 19 medical conditions that are weighted 1--6, with total scores ranging from 0 to 37. It is widely used to predict operation complications[@R26] and mortality caused by pneumonia and cancer,[@R27] and to control for confounding factors in epidemiological studies using claims data.[@R18] A previous study revealed that a CCI ≥3 is a risk factor for developing hospital-acquired pneumonia.[@R30] In this study, we confirmed that a high CCI score is associated with a high risk of pneumonia. A higher CCI score represents greater numbers of comorbidities and neurological consequences and a greater degree of immunocompromise. All of these conditions are risk factors for pneumonia, as described in previous literature.[@R31]

Another interesting finding is that low-income patients and those who live in rural areas exhibited an increased risk of developing pneumonia. The economy of Taiwan, a developed country, has been classified as advanced by the International Monetary Fund. Taiwan has 123 academic medical centres and 437 local community hospitals that service 23 million Taiwanese people. Healthcare services in Taiwan are managed by the Bureau of National Health Insurance, which reduces co-payments for low-income, disabled and elderly patients. Thus, seeking medical care in Taiwan is convenient and inexpensive. We attribute the low risk of pneumonia among low-income patients and those who live in rural areas to these characteristics of the Taiwanese healthcare system.

This study has some limitations. First, no clinical information was available on the Glasgow Coma Scale or Modified Rankin Scale scores of the stroke patients. Moreover, the neurological condition of the patients (such as dysphagia) was unclear. A previous study reported that dysphagia treated by feeding through a nasogastric tube is a predictor of the development of pneumonia in patients with ICH.[@R34] In this study, we used the CCI to partially overcome this limitation. Second, the database does not include information on over-the-counter PPI use or treatment compliance. Thus, the effect of PPI use may have been underestimated. Third, several potential lifestyle confounders that are associated with pneumonia, such as smoking, alcohol misuse, being underweight, having regular contact with children, and poor dental hygiene, were not included in the database. Therefore, further research on the relationship between PPIs and pneumonia in patients with non-traumatic ICH is required.

Conclusion {#s5}
==========

Our study reveals that the use of PPIs in patients with non-traumatic ICH is associated with an increased risk of pneumonia, and the severity of this risk varies according to the DDD. Physicians should exercise caution when prescribing PPIs to patients with non-traumatic ICH.
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